ライフサイエンスコーパス: tyrosine kinase 2

1 of the receptor, STAT1, Janus kinase 1, and tyrosine kinase 2.

2 concomitant phosphorylation of proline-rich tyrosine kinase 2.

3 bitory potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2.

4 activated the downstream kinase proline-rich tyrosine kinase 2.

5 ne phosphatase 1c with the receptor and with tyrosine kinase 2.

6 tein kinase C, Src kinases, and proline-rich tyrosine kinase 2.

7 inhibitor of the BMP6 receptor ALK receptor tyrosine kinase 2/3 or BMP6 siRNA identified BMP6 as a m

8 proteins were identified and include protein-tyrosine kinase 2 (also known as CAKbeta, RAFTK, and CAD

9 e kinase (RAFTK), also known as proline-rich tyrosine kinase 2 and cellular adhesion kinase beta, has

10 significant reduction of type I IFN-induced tyrosine kinase 2 and Jak1 phosphorylation.

11 associated with diminishing of IL-13-induced tyrosine kinase 2 and signal transducer and activator of

12 ted in lung and accompanied by activation of tyrosine kinase 2 and STAT1.

13 mely PKN2 (protein kinase N2), PTK2 (protein tyrosine kinase 2), and ALPP (alkaline phosphatase, plac

14 Syk, focal adhesion kinase, and proline-rich tyrosine kinase 2, and in the absence of Dectin-1.

15 tyrosine phosphorylation of Janus kinase 2, tyrosine kinase 2, and STAT3 and STAT4 transcription fac

16 contrast, inhibitors of Janus kinase 1/2 and tyrosine kinase 2, as well as the IFN-alpha/beta recepto

17 lzheimer's disease risk gene product protein tyrosine kinase 2 beta.

18 he phosphorylation and activation of protein-tyrosine kinase 2-beta (PTK2B, also referred to as Pyk2)

19 ing in macrophages, here we identify protein-tyrosine kinase 2-beta (PTK2B/PYK2) as a putative IRF5 k

20 tein 9 (CARD9) disturb the subsequent spleen tyrosine kinase 2-CARD9/BCL10/MALT1-driven signaling cas

21 ocess: a phospholipase C/Ca(2+)/proline-rich tyrosine kinase 2/cJun N-terminal kinase pathway.

22 ntrolene-sensitive, nonreceptor proline-rich tyrosine kinase-2; components of the extracellular signa

23 ype 3 (ITPR3), and discoidin domain receptor tyrosine kinase 2 (DDR2).

24 atelets, including the adapter downstream of tyrosine kinase 2 (Dok-2).

25 dicted that the 86 amino acids following the tyrosine kinase 2 domain of beta PDGFR (amino acid resid

26 tyrosine phosphorylation of the proline-rich tyrosine kinase 2, epidermal growth factor receptor (EGF

27 ogen receptor (ER)-positive, erb-b2 receptor tyrosine kinase 2 (ERBB2 [formerly HER2/neu])-negative (

28 , progesterone receptor, and erb-B2 receptor tyrosine kinase 2 (ERBB2 [formerly HER2]) expression, ma

29 AIMS: Drugs that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2) are the standard treat

30 Agents that inhibit the erb-b2 receptor tyrosine kinase 2 (ERBB2 or HER2), or vascular endotheli

31 the cell membrane, and that Erb-b2 receptor tyrosine kinase 2 (Erbb2) function is required for this

32 n, are effective in treating erb-b2 receptor tyrosine kinase 2 (ERBB2)-positive breast cancer (BC) th

33 In a mouse model of basal ErbB2 receptor tyrosine kinase 2 (ErbB2)-positive breast cancer (ErbB2(

34 Nonetheless, Erb-B2 receptor tyrosine kinase 2 (ERBB2, formerly HER2)-targeted biolog

35 Erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 [human epidermal

36 s regarding the prognosis of erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)-low

37 e receptor (HR)-positive and Erb-B2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)-neg

38 mone receptor-negative (HR-)/erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)-pos

39 e receptor (HR)-positive and erb-B2 receptor tyrosine kinase 2 (ERBB2; formerly HER2)-negative breast

40 mRNA expression of discoidin domain receptor tyrosine kinase 2, fibronectin, and alpha-smooth muscle

41 Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in

42 Gains in the targetable Erb-B2 receptor tyrosine kinase 2 gene were detected in 14% of GBC sampl

43 e with a 2538 G-->A missense mutation in the tyrosine kinase-2 gene (Tyk2) are susceptible to Toxopla

44 r protein-tyrosine kinase Pyk2 (proline-rich tyrosine kinase 2) has been shown previously to regulate

45 herapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orth

46 Inhibition of proline-rich tyrosine kinase 2 improved insulin-induced and shear str

47 the tyrosine phosphorylation of proline-rich tyrosine kinase 2 in acinar cells.

48 tein kinase C, Src kinases, and proline-rich tyrosine kinase 2 in the process.

49 ugh its receptor TrkB (neurotrophic receptor tyrosine kinase 2) in the pathophysiology of mood disord

50 Proline-rich tyrosine kinase 2, in turn, caused activation of the MAP

51 2 inhibitors (3.43 [95% CI, 2.14-5.49]), and tyrosine kinase 2 inhibitors (2.64 [95% CI, 1.44-4.86]).

52 The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Ge

53 ata further suggest that within this complex tyrosine kinase 2 is the tyrosine kinase responsible for

54 Pyk2 (proline-rich tyrosine kinase 2) is activated in cardiomyopathies and

55 ACK2 (activated Cdc42-associated tyrosine kinase-2) is a nonreceptor tyrosine kinase that

56 Janus tyrosine kinase 2 (JAK2) is essential for signaling by t

57 with the BCR-ABL fusion kinase and the Janus tyrosine kinase 2 (JAK2) V617F mutation, respectively.

58 As the Janus tyrosine kinase 2 (Jak2)/signal transducer and activator

59 ion of JAKs, all JAKs (JAK1, JAK2, JAK3, and tyrosine kinase 2), JAK2, or JAK3, caused a significant

60 ty, including focal adhesion kinase, protein tyrosine kinase-2, Janus kinase, other focal adhesion-as

61 20-fold or greater selectivity over JAK2 and Tyrosine kinase 2 kinases.

62 Lemur tyrosine kinase 2 (LMTK2) is a transmembrane protein wit

63 Lemur tyrosine kinase 2 (LMTK2) is involved in several physiol

64 ion study identified the gene encoding lemur tyrosine kinase-2 (LMTK2) as a susceptibility gene for p

65 y number amplifications in MYC-PTK2 (protein tyrosine kinase 2) locus and PIK3CA.

66 Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the regul

67 in kinase C delta and , but not proline-rich tyrosine kinase 2, mediate tumor necrosis factor alpha-i

68 Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomark

69 hat inhibition of both FAK1 and proline-rich tyrosine kinase 2 partially restored integrin beta1 expr

70 r necrosis factor-alpha-induced proline-rich tyrosine kinase 2 phosphorylation, but at different tyro

71 Because tyrosine kinase 2 plays a role in differentiation of Th

72 iR-495 is positively associated with protein tyrosine kinase 2 (PTK2) in both groups.

73 CH patients with higher pretreatment protein tyrosine kinase 2 (PTK2) messenger RNA levels derived gr

74 sion of one such gene, that encoding protein tyrosine kinase 2 (ptk2, also known as focal adhesion ki

75 ion kinase [FAK] family members proline-rich tyrosine kinase 2 [Pyk-2] and FAK) was also examined usi

76 Proline-rich tyrosine kinase 2 (pyk2) activity is enhanced under thes

77 as mediated by FA formation and proline-rich tyrosine kinase 2 (PYK2) activity.

78 focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) and also reduces the associatio

79 nd subsequent activation of the proline rich tyrosine kinase 2 (Pyk2) and Src family kinases, which i

80 focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) and their increased association

81 cells, phosphorylation of a FAK/proline-rich tyrosine kinase 2 (PYK2) consensus site in the alpha-hel

82 eceptor tyrosine kinase proline-rich protein tyrosine kinase 2 (Pyk2) functions as an integrator of m

83 tes the role of the nonreceptor proline-rich tyrosine kinase 2 (PYK2) in Ang II-induced VSMC protein

84 Despite the involvement of proline-rich tyrosine kinase 2 (Pyk2) in endothelial cell angiogenic

85 Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic tyrosine kinas

86 Proline-rich tyrosine kinase 2 (PYK2) is a cytoplasmic, non-receptor

87 Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesi

88 Proline-rich tyrosine kinase 2 (Pyk2) is a member of the focal adhesi

89 Proline-rich tyrosine kinase 2 (Pyk2) is a novel cytosolic tyrosine k

90 in vitro studies indicated that proline-rich tyrosine kinase 2 (PYK2) is a positive mediator of osteo

91 Proline-rich tyrosine kinase 2 (Pyk2) is activated by various agonist

92 , expression of the FAK-related proline-rich tyrosine kinase 2 (Pyk2) is elevated and phosphorylated

93 Protein tyrosine kinase 2 (Pyk2) is required for T cell adhesion

94 study in this issue shows that proline-rich tyrosine kinase 2 (Pyk2) is responsible for acid-induced

95 Proline-rich tyrosine kinase 2 (PYK2) is the main adhesion-induced ki

96 FAK and its homolog Proline-rich tyrosine kinase 2 (Pyk2) modulate paxillin activation; h

97 l that tyrosine kinases Src and proline-rich tyrosine kinase 2 (Pyk2) regulate SHP-1-dependent LPS-in

98 The proline-rich tyrosine kinase 2 (Pyk2) was first identified as a key k

99 Previous findings suggest that protein-tyrosine kinase 2 (PYK2), a cytoplasmic kinase related t

100 Proline-rich tyrosine kinase 2 (PYK2), a major cell adhesion-activate

101 Proline-rich tyrosine kinase 2 (PYK2), a redox-sensitive tyrosine kin

102 Proline-rich tyrosine kinase 2 (PYK2), a tyrosine kinase structurally

103 Proline-rich tyrosine kinase 2 (PYK2), also known as cell adhesion ki

104 Proline-rich tyrosine kinase 2 (PYK2), also known as cellular adhesio

105 n focal tyrosine kinase (RAFTK)/proline-rich tyrosine kinase 2 (PYK2), an upstream effector of JNK an

106 c TLR9 pathway engagement via MYD88, protein tyrosine kinase 2 (PYK2), and dedicator of cytokinesis 8

107 yrosine-protein kinase) and the proline-rich tyrosine kinase 2 (Pyk2), and they can also cause robust

108 The FAK-related kinase, proline-rich tyrosine kinase 2 (Pyk2), is expressed in FAK(-/-) cells

109 ns of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whe

110 am focal adhesion kinase (FAK)/ proline-rich tyrosine kinase 2 (PYK2), which are required for myeloid

111 vel substrate and interactor of proline-rich tyrosine kinase 2 (Pyk2).

112 rimary response gene-88 (MYD88)/proline-rich tyrosine kinase 2 (PYK2)/LYN complexes, which allows rec

113 the TLR4 cascade from activation of protein tyrosine kinase 2 (PYK2; also known as PTK2B).

114 egulated focal adhesion protein proline-rich tyrosine kinase-2 (Pyk2) and the effector proteins paxil

115 Here we demonstrate that proline-rich tyrosine kinase-2 (PYK2) deficiency impairs CD8 T-cell a

116 hosphorylation (Tyr-402) of the proline-rich tyrosine kinase-2 (PYK2) without significant change in a

117 al adhesion kinase (FAK) and/or proline-rich tyrosine kinase-2 (Pyk2), based on two lines of evidence

118 kinase Cs (aPKCs) by activating proline-rich tyrosine kinase-2 (PYK2), ERK pathway components, and ph

119 inhibitable; (b) dependent upon proline-rich tyrosine kinase-2 (PYK2), GRB2, SOS, RAS, RAF, and MEK1;

120 revious research identified the proline-rich tyrosine kinase 2, Pyk2, as a critical mediator of GC-in

121 Inhibition of proline-rich tyrosine kinase 2 restores insulin-induced and shear str

122 dysfunction through inhibition of the IL-13/tyrosine kinase 2/signal transducer and activator of tra

123 al Nrg1 to myocardial ErbB2 (erb-b2 receptor tyrosine kinase 2) signaling and phospho-Erk (phosphoryl

124 cules downstream of the IFN receptor, namely tyrosine kinase 2, STAT1, and IFN regulatory factor 7, a

125 transcription (STAT) family, including JAK1, tyrosine kinase 2, STAT2, and STAT4 in the human progeni

126 that in cells expressing RAFTK/proline-rich tyrosine kinase 2, such as endothelial and B cells, RAFT

127 remodeling pathways (ERBB2 [erbb-b2 receptor tyrosine kinase 2], TGFB1 [transforming growth factor-be

128 ibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermat

129 Y657 of eNOS and expression of proline-rich tyrosine kinase 2 that phosphorylates this residue were

130 G protein and to PLC-gamma via a downstream tyrosine kinase; 2) the initial AT1 receptor-PLC-beta1 c

131 he JAK family includes JAK1, JAK2, JAK3, and tyrosine kinase 2; the STAT family includes STAT1, STAT2

132 NG-2 binds the endothelial-specific receptor tyrosine kinase 2 (TIE2) and acts as a negative regulato

133 ion of the angiopoietin receptor endothelial tyrosine kinase 2 (Tie2) or both angiopoietin-1 and angi

134 -specific tunica intima endothelial receptor tyrosine kinase 2 (Tie2) receptor kinase, angiopoietin-1

135 rotective tunica intima endothelial receptor tyrosine kinase 2 (Tie2).

136 necrosis factor-alpha activates proline-rich tyrosine kinase 2 to cause cytoskeletal disorganization

137 t-Aldrich syndrome protein, nor proline rich tyrosine kinase-2 to the target cell contact site.

138 ly performed genetic screens that identified tyrosine kinase 2 (TYK2) as a candidate regulator of tau

139 reduced the cellular level of expression of tyrosine kinase 2 (TYK2) at 12 hpi.

140 ive (CYT387), which inhibits JAK1, JAK2, and tyrosine kinase 2 (TYK2) at low nanomolar concentrations

141 We report here that novel Tyrosine kinase 2 (Tyk2) gene mutations are present in v

142 Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, blocks IL-23, IL-12,

143 Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, is a potential new o

144 Tyrosine kinase 2 (TYK2) is a member of the JAK kinase f

145 Tyrosine kinase 2 (TYK2) is a member of the JAK kinase f

146 Tyrosine kinase 2 (TYK2) is a nonreceptor tyrosine kinas

147 Tyrosine kinase 2 (TYK2) is a widely expressed receptor-

148 Tyrosine kinase 2 (TYK2) mediates cytokine signaling thr

149 cule inhibitor with specificity for JAK1 and tyrosine kinase 2 (TYK2) over other JAK family members.

150 mily of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling throu

151 cent study, Kim and colleagues decipher that tyrosine kinase 2 (TYK2) phosphorylates tau at tyrosine

152 Here, we review tyrosine kinase 2 (TYK2) signaling in the pathophysiolog

153 edictions include a microRNA in an intron of tyrosine kinase 2 (TYK2) that is present in both cat and

154 GWAS have identified tyrosine kinase 2 (TYK2) variants in multiple inflammato

155 cure, but we demonstrate that IL-22 acts via tyrosine kinase 2 (Tyk2), a member of the Jak family.

156 components, including Janus kinase 1 (JAK1), tyrosine kinase 2 (Tyk2), and the interferon receptor su

157 tors 1 and 2 (IFNAR1, IFNAR2, respectively), tyrosine kinase 2 (Tyk2), Jak1, and STAT2 are assembled

158 xis, connecting genetic aberrations in FLT3, tyrosine kinase 2 (TYK2), platelet-derived growth factor

159 the pseudokinase domain of the Janus kinase tyrosine kinase 2 (Tyk2), resulting in blockade of recep

160 that MEOX1 knockdown decreased expression of tyrosine kinase 2 (TYK2), signal transducer and activato

161 el tyrosine kinase that phosphorylates Cx43, tyrosine kinase 2 (Tyk2).

162 for interferon (IFN)-regulated pathways and tyrosine kinase 2 (TYK2).

163 of phosphorylated Janus kinase 1 (JAK1) and tyrosine kinase 2 (Tyk2).

164 se family, and brepocitinib, an inhibitor of tyrosine kinase 2 (TYK2)/JAK1 in the treatment of AA.

165 P = 2.3 x 10(-8)) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3 (rs21090

166 P = 2.3 x 10(-8)) near the gene that encodes tyrosine kinase 2 (TYK2); on chromosome 19p13.3) within

167 Concomitantly, IFN-alpha stimulation of tyrosine kinase 2 tyrosine phosphorylation and kinase ac

168 tein kinase C delta and mediate proline-rich tyrosine kinase 2 tyrosine phosphorylation.

169 t al. now show that mutation of another Jak, tyrosine kinase 2, underlies another human immunodeficie

170 comprises four members, JAK1, JAK2, JAK3 and tyrosine kinase 2, which are critical for intracellular

171 small interfering RNA targeting proline-rich tyrosine kinase-2, which was also phosphorylated in resp